Can live-attenuated SARS-CoV-2 vaccine contribute to stopping the pandemic?
File version
Version of Record (VoR)
Author(s)
Ng, Wern Hann
King, Nicholas JC
Mahalingam, Suresh
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Abstract
Coronavirus Disease 2019 (COVID-19) has plagued the world throughout 2020 to 2022, with over 580 million confirmed cases and 6.4 million deaths. Several vaccines have been approved for human use, including those from Pfizer-BioNTech, Moderna, Novavax, AstraZeneca, Johnson & Johnson, and Sinovac. The focus on rapid vaccine platforms such as mRNA, adenovirus vectors, DNA vectors, inactivated and subunit vaccines for COVID-19 [1] allowed the introduction of COVID-19 vaccines for human use in record time.
Journal Title
PLoS Pathogens
Conference Title
Book Title
Edition
Volume
18
Issue
9
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2022 Tang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Item Access Status
Note
Access the data
Related item(s)
Subject
Microbiology
Immunology
Medical microbiology
Persistent link to this record
Citation
Tang, PCH; Ng, WH; King, NJC; Mahalingam, S, Can live-attenuated SARS-CoV-2 vaccine contribute to stopping the pandemic?, PLoS Pathogens, 2022, 18 (9), pp. e1010821